References
- Anonymous. Where next with psychiatric illness?. Nature 1988; 336: 95–96
- Balant-Gorgia A.E., Balant L. Antipsychotic drugs, clinical pharmacokinetics of potential candidates for plasma concentrations monitoring. Clin. Pharmacokinet. 1987; 13: 65–90
- Bhalla H.L., Bhate A.S. Feasibility studies on transdermal films of ephedrine. Indian Drugs 1994; 31(7)328–332
- Crane G.E. Tardive dyskinesia and related neurologic disorders. Handbook of Psychopharmacology. Plenum Press, New York 1978; Vol. 10: 165–196
- Casey D.E. Tardive dyskinesia (Review). West. J. Med. 1990; 153(5)535–541
- Casey D.E. Neuroleptic drug induced extra pyramidal syndromes and tardive dyskinesia (Review). Schizophrenia Res. 1991; 4(2)109–120
- Desai S.M., Sahajwala C.G., Lalla J.K. Chlorpromazine hydrochloride in controlled release dosage forms: derivation of a two compartment open model for determining its desired concentrations in the formulations. Indian Drugs 1990; 27(9)462–471
- Gerken A., Wetzel H., Benkert O. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting test study in 22 acutely ill schizophrenic patients. Pharmacopsychiatry 1991; 24(4)132–137
- Glazer W.M., Kane J.M. Depot neuroleptic therapy: an underutilized treatment option. J. Clin. Psychiatry 1992; 53: 426–433
- Gibbered F.B. Management of Parkinson's disease. Br. Med. J. 1987; 294: 1393–1394
- Howells J.G. The Concept of Schizophrenia: Historical Perspectives, 1st Ed. American Psychiatric Press, Washington 1991; 18
- Horiguchi J., Nishimatsu O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double blind study. Japanese J. Psychiatr. Neurol. 1992; 46(3)733–739
- Huimin H., Weiguo G., Meisen Z., Yazhen W., Lixi S., Songsheng G., Dingcai P. Preparation and bioavailability of controlled release tablets of chlorpromazine hydrochloride. Yiyao Gongye 1988; 19(8)355–358
- Johnson D.A.W., Pasterski G., Ludlow J.M., Strect K., Taylor R.D.W. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients; Drugs and social consequences. Acta Psychiatrica Scandinavica 1983; 67: 339–352
- Jenner P., Marsden C.D. Adaptive changes in brain dopamine function as a result of neuroleptic treatment. Adv. Neurol. 1988; 49: 417–431
- Kulkarni S.K. Handbook of Experimental Pharmacology, 2nd Ed., M.K. Jain. Vallabh Prakashan, Delhi 1987; 62
- Klawans H.L., Tanner C.M., Goetz C.G. Epidemiology and phathophysiology of tardive dyskinesia. Adv. Neurol. 1988; 49: 185–197
- Katsumi M., Takaichi A., Hari O, Tsukasa K, Itaru V. High performance liquid chromatography determination of haloperidol in plasma. J. Chromatogr. 1991; 223: 449–453
- Lalla J.K., Seethalakshmi K.R., Dattani K.K. Nitroglycerin controlled release transdermal patch. Indian Drugs 1989; 26(6)284–295
- Misra A.N. Transdermal drug delivery. Controlled and Novel Drug Delivery, N.K. Jain. CBS Publishers and Distributors, New Delhi 1997; 100–129
- Malhotra A.K., Litman R.E., Pickar D. Adverse effects of antipsychotic drugs (Review). Drug Safety 1993; 9(6)429–436
- Menon M.K., Dandiya P.C. The mechanism of tranquilizing action of asarone from Acorus calamus. J. Pharm. Pharmacol. 1967; 19: 170–175
- Mukherjee P.K., Kakali S., Balasubramaniam R., Pal M., Saha B.P. Studies on the psychopharmacological effects of Nelumbo nucifera Gaeotn. Rhizome extract. J. Ethnopharmacol. 1996; 54(2,3)63–67
- Pradas T.N., Sivakumar M. HPLC quantification of a tricomponent psychiatric formulation containing Chlorpromazine, trifluoperazine, trihexyphenidyl. Pharmazie 1992; 47(3)231
- Vyas S.P., Dixit V.K. Development and performance evaluation of controlled release osmo-sinosules of chlorpromazine hydrochloride. Drug Dev. Ind. Phar. 1990; 16(15)2325–2338
- William T., Carpenter J.R., Robert W.B. Medical progress: schizophrenia. The New England Journal of Medicine 1994; 330: 681–690